SK bioscience, a Korean firm, emerged as a key vaccine developer, notably during COVID-19. Spun off in 2018, it partnered with AstraZeneca for COVID-19 vaccine production and developed the SKYCovione vaccine. The company expanded its portfolio to include vaccines for pneumococcal infections, Ebola, and typhoid. Yong Wook Park, SK's VP of biological R&D, highlighted their diverse vaccine lineup, emphasizing the importance of protein-subunit vaccines due to their proven safety and cost-effective distribution. Manufacturing involves various hosts and purification methods, with scalability crucial for global demand. Adjuvants enhance immune responses, reducing antigen doses. Challenges include meeting regulations while ensuring yield and speed. SK aims to respond swiftly to future outbreaks, leveraging its platform technologies. This summary underscores SK bioscience's vital role in vaccine development, emphasizing protein-subunit vaccines alongside mRNA options.